December 09, 2016 4:48 AM ET


Company Overview of Tokai Pharmaceuticals, Inc.

Company Overview

Tokai Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases. Its lead drug candidate is galeterone, an oral small molecule that is in various clinical trials for the treatment of patients with metastatic castration-resistant prostate cancer. The company’s androgen receptor degradation (ARDA) drug discovery program is focused on identifying and developing compounds for ARDA activity. Tokai Pharmaceuticals, Inc. was founded in 2004 and is based in Boston, Massachusetts.

255 State Street

6th Floor

Boston, MA 02109

United States

Founded in 2004

24 Employees



Key Executives for Tokai Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 41
Total Annual Compensation: $475.0K
Compensation as of Fiscal Year 2015.

Tokai Pharmaceuticals, Inc. Key Developments

Tokai Pharmaceuticals, Inc. Announces Resignation of Timothy J. Barberich as a Member of the Board of Directors

Timothy J. Barberich notified Tokai Pharmaceuticals, Inc. of his resignation as a member of the board of directors of the company and the compensation, audit and nominating and corporate governance committees thereof, effective immediately. Mr. Barberich's decision to resign did not result from any disagreement with the company on any matter relating to the Company's operations, policies or practices.

WeissLaw LLP Announces Class Action Lawsuit against Tokai Pharmaceuticals, Inc

WeissLaw LLP announced that a class action has been filed in the United States District Court for the Southern District of New York against Tokai Pharmaceuticals, Inc. and certain company officers, for among other things, violation of sections 10(b) and 20(a) of the Securities and Exchange Act of 1934. The class action seeks to pursue remedies on behalf of all person or entities who purchased or otherwise acquired shares of Tokai between June 24, 2015 and July 25, 2016. The complaint alleges that defendants made materially false and/or misleading statements, as well as failed to disclose information with regard to Tokai's operations and compliance policies by: failing to inform and/or misrepresent the structural problems of phase 3 of the Galeterone trial to shareholders, which subsequently resulted in the failure of the trial; and filing materially false and/or misleading financial statements.

Tokai Pharmaceuticals Announces Review of Strategic Alternatives

Tokai Pharmaceuticals, Inc. (NasdaqGM:TKAI) announced that its Board of Directors has initiated a review of strategic alternatives to focus on maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated as part of this review include a sale of the company, a reverse merger, a business combination or a sale, license or other disposition of corporate assets of the company. There is no set timetable for this process and there can be no assurance that this process will result in any such transaction.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tokai Pharmaceuticals, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at